Correction to: J Transl Med (2021) 19:192 https://doi.org/10.1186/s12967-021-02860-z
In the original publication [1] there was an incorrect funding section. The incorrect and correct funding information is published in this correction article. The original article has been updated.
Incorrect funding
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (Grant Number HI20C1496), the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. NRF-2018R1A2B6007291) and (No. NRF-2018R1C1B6005889).
Correct funding
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (Grant Number HI20C1496, HI15C3062), the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. NRF-2018R1A2B6007291) and (No. NRF-2018R1C1B6005889).
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Jeonghyeon Moon and Seon-yeong Lee contributed equally to this work
Reference
- 1.Moon J, Lee S, Choi JW, Lee AR, Yoo JH, Moon S-J, Park S-H, Cho ML. Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts. J Transl Med. 2021;19:192. doi: 10.1186/s12967-021-02860-z. [DOI] [PMC free article] [PubMed] [Google Scholar]